IGC Pharma (IGC) announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation in Alzheimer’s dementia, to MIND Institute at Miami Jewish Health in Miami, Florida. This addition further advances the company’s efforts to accelerate the trial’s completion and builds on promising interim data suggesting the potential of IGC-AD1 to improve patient outcomes. The trial at Miami Jewish Health will be led by Dr. Marc E. Agronin, a nationally recognized geriatric psychiatrist and Chief Medical Officer of MIND Institute
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGC:
- IGC Pharma announces interim data from Phase 2 trial of IGC-AD1
- IGC Pharma announces additional interim results from IGC-AD1 trial
- IGC Pharma announces CALMA Phase 2 trial expansion
- IGC Pharma expands CALMA trial with addition of BayCare Health System
- IGC Pharma develops AI-driven model to improve diagnosis of Alzheimer’s